RecruitingPhase 2NCT06029270
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Brigette B MaNRG Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 156 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- Kaiser Permanente Dublin, Dublin, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- Kaiser Permanente Fresno Orchard Plaza, Fresno, California, United States
- Kaiser Permanente-Fresno, Fresno, California, United States
- Keck Medicine of USC Koreatown, Los Angeles, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Kaiser Permanente- Modesto MOB II, Modesto, California, United States
- Kaiser Permanente-Modesto, Modesto, California, United States
- USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- Kaiser Permanente-Roseville, Roseville, California, United States
- Kaiser Permanente Downtown Commons, Sacramento, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06029270 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh